DSS India – Drug Safety Symposium
Drug Safety Symposium 2024
India Chapter

June 28th – 27th, 2024
Unity in Safety: Elevating Indian Pharmacovigilance to Global Excellence

Download Agenda
Enhancing Quality Assurance

At Drug Safety Symposium 2024, we are at the forefront of ensuring drug safety through the rigorous practices of pharmacovigilance, regulatory compliance, and quality assurance. Our premier gathering provides a dynamic platform where attendees can explore the latest industry trends, stay updated on regulatory changes, and discover innovative solutions that drive the pharmaceutical industry forward. We are committed to excellence and facilitating meaningful discussions, knowledge sharing, and collaboration.

Book Now
Why Drug Safety Matters

In an ever-evolving pharmaceutical landscape, the importance of drug safety cannot be overstated. Each day, countless lives depend on the efficacy and safety of pharmaceutical products. Our mission is to advance the critical mission of ensuring that every drug is not only effective but also safe for consumption.

Book Now
A Uniquely Engaging Event

What sets Drug Safety Symposium 2024 apart is our unique approach. We combine insightful knowledge sharing with interactive workshops and networking opportunities, all in an atmosphere of camaraderie and fun. It's not just an event; it's an experience that empowers you to make informed decisions and contribute to the highest standards of drug safety and quality.

Book Now
Previous slide
Next slide
Days
Hours
Minutes
Seconds

Our Commitment

Your perception is our reality, that’s what makes us different! Here’s what we do to deliver exceptional content.
Media Partner Drug Safety-17

Global Thought Leadership

Our conference brings together the leading experts, thought leaders and regulators to provide unparalleled insights into the latest trends and challenges shaping the industry.
Media Partner Drug Safety-2

Interactive Learning

Our unique approach ensures a holistic and engaging experience for our attendees. Our conferences are not just about passive listening; it's about active participation. Gain practical insights and actionable takeaways that you can apply immediately in your role.
Media Partner Drug Safety-23

Cutting-Edge Technology

Explore the latest technological advancements and software solutions that are transforming pharmacovigilance practices, offering efficiency and compliance.
Media Partner Drug Safety-22

Regulatory Insights

Gain direct access to regulatory authorities and compliance experts who provide valuable insights into regional and international pharmacovigilance regulations.

Speakers

SCIENTIST-E in QMS & REGULATORY, AMTZ, Vizag
(Former Drug Controller of India)

Dr. Somnath Basu

Head- Global Pharmacovigilance

Dr. Rahul Somani

Head-Pharmacovigilance · Emcure Pharmaceuticals

Dr. Neha Vala

Vice President – Pharmacovigilance and Medico-regulatory affairs at Ipca Laboratories Ltd.

Geeta Shanbhag

CEO & Founder, PVCON

Pr. Moin Don

Dy. QPPV (Asst GM) - Clinical Research & PV,
Serum Institute of India
Mr. Chetanraj Bhamare

Global Head Pharmacovigilance, Lupin

Dr. Chitra Bargaje

Vice President and Global Head - Pharmacovigilance, Glenmark
Pharmaceuticals
Mr. Rajendra Kumar Kasi

Global Head - Pharmacovigilance, Cipla
Mr. Prasad Deshmukh

Partners

Why Partner at Drug Safety Symposium 2024 – India Chapter?

By partnering with us, you can position your brand at the forefront of the pharmaceutical landscape and gain invaluable exposure to a highly targeted and influential audience.

Partnering with the Drug Safety Symposium 2024 is a strategic investment, to explore sponsorship opportunities and discuss customized packages, please contact us at [email protected]

India

What Can You Do In Mumbai

Gateway of India 

Juhu Beach

Prithvi Cafe

Jehangir Art Gallery

Marine Drive

Scroll to Top

Dr. Somnath Basu

SCIENTIST-E in QMS & REGULATORY, AMTZ, Vizag
(Former Drug Controller of India)

With a robust academic background in Chemistry (Honors) and Biochemistry (Masters) encompassing Molecular Biology, Microbiology, and Genetics, Dr. Basu earned his Ph.D. from Calcutta University. His professional journey began at CDL-Calcutta, a WHO collaborating center and National Appellate lab for drug analysis, where he acquired over 6 years of expertise in analytical techniques such as HPLC, GC, IR, and Microbial Assay.
Currently, serving as a Scientist-E at AMTZ, Vizag, specializing in Quality Management Systems and Regulatory affairs. In his previous role at CDSCO, he led a team of reviewers for the regulation of new drugs, recombinant drugs, vaccines, stem cell therapeutics, medical devices, and in-vitro diagnostics. He also served as the focal person for WHO-NRA assessments since 2007, contributing to the strengthening of the Indian Drug Regulatory Authority.
Throughout his career, he has collaborated with various departments and organizations, including the Ministry of Health, Ministry of Revenue, Ministry of Agriculture, QCI, BIS, NIB, IPC, PvPI, AEFI Secretariat, Immunization Division of GoI, CDL (Kasauli), DBT, THSTI/CDSA, and the Department of Animal Husbandry.

Dr. Rahul Somani

Global Head – PV, Alkem Laboratories

I have been with Alkem Laboratories Ltd, Mumbai, for the past 13 years in various roles and am currently serving as the Head of Global Pharmacovigilance.
With 25 years of experience spanning both academic and industrial roles, I have played a key role in establishing an in-house Pharmacovigilance department that adheres to stringent regulatory standards and processes. This has supported our global pharmacovigilance operations through the development and implementation of comprehensive safety monitoring systems, risk management plans, and regulatory compliance strategies.
In the past five years, I have successfully led my team through three major regulatory inspections for Pharmacovigilance by the USFDA, TGA-Australia, and MoH-Kazakhstan. These inspections required meticulous preparation and a deep understanding of regulatory requirements, affirming the robustness and effectiveness of our pharmacovigilance practice.

Dr. Neha Vala

Head-Pharmacovigilance · Emcure Pharmaceuticals

Dr. Neha Vala is a seasoned medical professional (M.B.B.S) with approximately 17 years of experience in pharmacovigilance, clinical research, and medical domains.
She has an extensive training in basic and clinical pharmacology, global pharmacovigilance guidelines, MedDRA, and GCP. She possesses comprehensive knowledge of global pharmacovigilance requirements with expertise in risk management planning, signal management, and periodic risk-benefit evaluation.
With a proven track record of establishing pharmacovigilance functions/units for various pharmaceutical companies, Dr. Neha is experienced in managing multiple regulatory inspections, including those by MHRA, US FDA, Health Canada, and other EU authorities, as well as conducting numerous client audits.
She is a recognized speaker at numerous national and international pharmacovigilance conferences.

Geeta Shanbhag

Vice President – Pharmacovigilance and Medico-regulatory affairs at Ipca Laboratories Ltd.

Currently, Geeta Shanbhag is working as Vice President – Pharmacovigilance and Medico-regulatory affairs at Ipca Laboratories Ltd.
A management post graduate with pharmacy background, she has around three decades of experience in pharmaceutical industry, inclusive of medico-marketing, regulatory affairs, clinical research, bioequivalence studies, pre-clinical studies and pharmacovigilance.
She is a proactive team player with strong planning skills, critical/ analytical thinking, multitasking, problem solving, and team management skills.
From past 15 years, she is involved in pharmacovigilance. She has been instrumental in setting up in house pharmacovigilance department in Ipca, which handles end to end pharmacovigilance on global scale. She has also initiated automation of various pharmacovigilance related processes such as auto-labelling, auto-narratives, learning management system, electronic document management system, quality management system, medical inquiry system and android mobile application for adverse event reporting.
She has hands on experience on both Aris G and Argus database, data migration, case processing, medical writing in pharmacovigilance, vendor management, safety data exchange agreements, Trackwise software for Quality Management System, audits and inspections. In fact, Ipca successfully cleared its first US FDA pharmacovigilance inspection in 2017.